Brainomix announces new partnership with Pixyl

Published by

Peter Davison

Oxford-based AI-powered medtech solutions company Brainomix has announced a new partnership with Pixyl, an award-winning, Grenoble-based medtech specialising in medical neurology imaging.

As part of the collaboration, Brainomix will distribute Pixyl’s Neuro.MS Software as a Service solution, which is used in the diagnosis and treatment of patients with multiple sclerosis.

BrainomixPixyl's revolutionary deep-learning technology allows radiologists and clinicians to quickly access clinically relevant information for neurological disorders like multiple sclerosis.

The CE-marked class IIa product Neuro.MS automatically analyses brain MRI images to identify, quantify and track abnormalities in under 5 minutes. This provides access to quantified measures of lesion volume and brain atrophy, as well as white matter hyperintensities, which are quantified and classified.

Brainomix will be distributing Pixyl.Neuro SaaS solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe.

“We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions,” noted Dr Michalis Papadakis, Co-Founder and CEO of Brainomix.

“We recognized that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions.

"We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”

Pixyl’s Neuro.MS solution will be offered to Brainomix’s existing customer base alongside Brainomix’s e-Stroke platform, the world’s most comprehensive stroke imaging solution, which is widely adopted in multiple healthcare systems worldwide, supporting physicians to allow more patients to be treated in the right place, at the right time.

“Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space,” noted Senan Doyle, Co-Founder and CEO of Pixyl.

The emergence of disease-modifying drugs now offers more personalised treatment of multiple sclerosis, a neurological disorder that affects more than 2.3 million people worldwide.

This has elevated the role of MRI in supporting both the diagnosis and ongoing disease monitoring and treatment response, opening the door for AI-powered solutions such as Pixyl’s Neuro.MS software to improve diagnosis and speed up treatment.

Peter Davison

Peter Davison is deputy editor of The Business Magazine. He has spent his life in journalism – doing work experience in newsrooms in and around Bristol while still at school, and landing his first job on a local newspaper aged 19. By 28 he was the youngest newspaper editor in the country. An early advocate of online news, he spent the first years of the 2000s telling his bosses that the internet posed both the biggest opportunity and greatest threat to the newspaper industry and the art of journalism. He was right on both counts. Since 2006 he has enjoyed a career as a freelance journalist. He lives in rural Wiltshire with one wife, two children, and three cats.